Coagulation abnormalities and their neuro-ophthalmologic manifestations

Current Opinion in Ophthalmology

Volumn 10, Issue 6, 1999, Pages 382-393

  Biousse, Valérie ^a  

^a EMORY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

ARTICLE; BLOOD CLOTTING DISORDER; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; ISCHEMIC OPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; SICKLE CELL ANEMIA; VEIN THROMBOSIS; VISUAL IMPAIRMENT;

BLOOD COAGULATION FACTORS; CENTRAL NERVOUS SYSTEM DISEASES; EYE DISEASES; HEMOSTASIS; HUMANS; THROMBOPHILIA; THROMBOSIS;

EID: 0032749042     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199912000-00004     Document Type: Article

References (85)

1. 1 Thomas DP, Roberts HR: Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997, 126:638-644.
2. 2 De Stefano V, Finazzi G, Mannucci PM: Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 1996, 87:3531-3544.
3. 3 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al.: Inherited thrombophilia: part I. Thromb Haemost 1996, 76:651-662.
4. 4 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al.: Inherited thrombophilia: part II. Thromb Haemost 1996, 76:824-834.
5. 5 Rosenberg RD, Aird WC: Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999, 340:1555-1564. This review of the concept of "vascular-bed-specific hemostasis and hypercoagulable states" explains why a systemic hypercoagulable state generally gives a focal thrombosis.
6. 6 Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 1999, 353: 1167-1173. This is an excellent review on venous thrombosis.
7. 7 Bertina RM, Rosendaal FR: Venous thrombosis. The interaction of genes and environment. N Engl J Med 1998, 338:1840-1841. This superb editorial discusses the role of genetic hypercoagulable states in the development of venous thrombosis and the interaction of these states with acquired risk factors, such as use of oral contraceptives.
8. 8 Martinelli I, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, et al.: Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998, 92:2353-2358. These authors compared lifetime probability for thrombosis, type of thrombotic symptoms, and role of triggering factors in 723 first-and second-degree relatives of 150 index patients with various thrombophilic defects (antithrombin, protein C, and protein S deficiencies and ARC resistance). Risk for thrombosis was higher in persons with antithrombin deficiency (relative risk, 8.1), protein C deficiency (relative risk, 7.3), protein S deficiency (relative risk, 8.5), and factor V Leiden mutation (relative risk, 2.2) than in persons with normal coagulation. The risk for thrombosis was lower in persons with the factor V Leiden mutation than in persons with all three of the other coagulation defects. No association was found between coagulation defects and arterial thrombosis. The most common thrombotic manifestation was deep vonous thrombosis with or without pulmonary embolism. A predisposing factor at the time of venous thrombosis was seen in approximately 50% of cases for each of the four defects.
9. 9 Francis JL: Laboratory investigation of hypercoagulability. Semin Thromb Hemost 1998, 24:111-126. This is a very useful, practical review of the laboratory investigation and management of hypercoagulable states.
10. 10 Price DT, Ridker PM: Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997, 127:895-903.
11. 11 De Stefano V, Chiusolo P, Paciaroni K, Leone G: Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost 1998, 24:367-379. The factor V Leiden allele is present in about 5% of white persons (Europeans, Jews, Israeli Arabs, and Indians). It is virtually absent in Africans; Asians; and groups with Asian ancestry, such as Amerindians, Eskimos, and Polynesians. A low prevalence of the mutation (1%) was noted in African-Americans of recent racial admixture. The mutation does not have a major role as a risk factor for arterial thrombosis, although it is present in 18% of white persons with venous thrombosis. Conversely, the mutation is usually not found in nonwhite patients with thrombosis; this may explain why the incidence of venous thrombotic disease is lower in Africa and Asia than in Europe.
12. 12 Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, et al.: Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997, 89: 2817-2821.
13. 13 Margagtione M, Brandaccio V, Giuliani N, D'Andrea G, Cappucci G, Iannaccone L, et al.: Increased risk for venous thrombosis in carriers of the prothrombin G → A20210 gene variant. Ann Intern Mod 1998, 129:89-93.
14. 14 Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Ragnunathan TE, Vos HL: A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997, 90:1747-1750.
15. 15 De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, et al.: Prothrombin G20210A mutant phenotype is a risk factor for cerebrovascular disease in young patients. Blood 1998, 91:3562-3565. The factor II G20210A mutation was studied in 72 patients with cerebral infarction and no vascular risk factors and in 198 controls without thrombosis. Seven persons heterozygous for the mutant factor allele (9.7%) and two persons homozygous for this allele (2.7%) were found among the patients, and five heterozygotes (2.5%) were found among the controls. The frequency of the mutant factor II allefe was significantly higher in the patient group (7.6%) than in the control group (1.2%). The odds ratio for ischemic stroke associated with carriership of the mutant factor II allele was 5.1. The heterozygous genotype was associated with a 3.8-fold increased risk for cerebral ischemia.
16. 16 Steinberg MH: Management of sickle cell disease. N Engl J Med 1999, 340: 1021-1030. This is a review of new and emerging treatments for sickle cell disease.
17. 17 Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al.: Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998, 91:288-294. The Cooperative Study of Sickle Cell Disease collected clinical data on 4082 patients with sickle cell disease enrolled from 1978 to 1988. Patients were followed for an average (±SD) of 5.2±2.0 years. The highest rales of prevalence (4.01%) and incidence (0.61 per 100 patient-years) of cerebrovascular accident were seen in patients with sickle cell anemia, but cerebrovascutar accident occurred in all common genotypes. The incidence of ischemic stroke was lowest in patients with sickle cell disease who were 20 to 29 years of age and was higher in children and older patients. Conversely, the incidence of hemorrhagic stroke in patients with sickle cell disease was highest among patients 20 to 29 years of age. Across all ages, the mortality rate was 26% in the 2 weeks after hemorrhagic stroke. No deaths occurred after ischemic stroke. Risk factors for ischemic stroke included previous transient ischemic attack, recent episode of acute chest syndrome, elevated systolic blood pressure, and low steady-state hemoglobin concentration and rate.
18. 18 Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al.: Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med 1998, 339:5-11. Transcranial Doppler ultrasonography is a useful, noninvasive method for identifying children with sickle cell disease who are at risk for stroke and may benefit from prophylaxis with periodic blood transfusion. This article presents the results of a trial in which 130 children were randomly assigned to receive 1) periodic transfusions to obtain a hemoglobin S concentration less than 30% of total hemoglobin (n = 63) or 2) standard care (n = 67). Ten cerebral infarctions and one cerebral hematoma occurred in the standard-care group, and one infarction occurred in the transfusion group, for a 92% difference in risk for stroke (P<0.001). This result led to early termination of the trial.
19. 19 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V mutation. Lancet 1994, 344:1453-1457.
20. 20 De Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP, for the Cerebral Venous Sinus Thrombosis Study Group: Case control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ 1998, 316:589-592. This prospective study compared the current use of oral contraceptives in 40 women 18 to 54 years of age with CVT (case-patients) and 2248 women 18 to 49 years of age (controls). Thirty-four women with CVT (85%) and 1007 controls (45%) used oral contraceptives. The age-adjusted odds ratio for CVT was 13 (95% Cl, 5 to 37). Seven of 36 patients (19%), compared with the 7% expected in the population, had a prothrombotic deficiency; this corresponds to a three-to four-fold increase in risk. In women who used contraceptives and also carried a prothrombotic defect compared with women who had neither risk factor, the odds ratio for CVT was about 10.
21. 21 Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannussi PM: High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998, 338:1793-1797. This study shows that 35% of patients with CVT have a hypercoagulable state. The most frequent coagulation abnormality is the G20210A mutation in the prothrombin gene, which increases risk for CVT by a factor of 10. This study also indicates that oral contraceptives are strongly associated with CVT, increasing risk for CVT by a factor of 20. Although the number of women with both the prothrombin gene mutation and the use of oral contraceptives was small, the combination of these two risk factors greatly increased risk for CVT.
22. 22 Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WBJ, Bos GMJ: Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998, 80:874-877.
23. 23 Ridker PM, Manson JOE, Buring JE, Shih J, Matias M, Hennekens CH: Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999, 281:1817-1821. In this prospective study of 28,263 healthy postmenopausal US women, elevated homocysteine levels (>20.7 μmol/L) at baseline increased risk for future myocardial infarction and stroke (relative risk, 2.2). Self-reported multivitamin supplement use at study entry was associated with significantly reduced homocysteine levels (P<0.001) but was not associated with a significantly reduced risk for myocardial infarction or stroke.
24. 24 Neugebauer S, Baba T, Kurokawa K, Watanabe T: Defective homocystein metabolism as a risk factor for diabetic retinopathy. Lancet 1997, 349:473-474.
25. 25 Brattstrom L, Wilcken DEL, Ohrvik J, Brudin L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998, 98:2520-2526.
26. 26 Rimm EB, Willet WC, Hu FB, Sampson L, Colditz GA, Manson JE, et al.: Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998, 279:359-364.
27. 27 Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999, 340:1449-1454. The effect of folic acid fortification (140μg/100 g) of all enriched grain products was assessed in 350 patients and controls in the Framingham Offspring Study cohort (a population of middle-aged and older adults) through the measurement of plasma folate and total homocysteine concentrations. This fortification was associated with an increase in mean folate concentration and a decrease in total homocysteine concentration. Because a high concentration of homocysteine is a proven risk factor for vascular disease, folic acid fortification would probably have a measurable effect on the rate of cerebrovascular and coronary heart disease in the United States.
28. 28 Greaves M: Antiphospholipid antibodies and thrombosis. Lancet 1999, 353: 1348-1353. This recent review discusses the definitions of primary and secondary antiphospholipid syndrome and the diagnosis and management of these conditions.
29. 29 Tanne D, Triplett DA, Levine SR: Antiphospholipid-protein antibodies and ischemic stroke. Not just cardiolipin any more. Stroke 1998, 29:1755-1758. In this excellent editorial on the definition of aPLs, the authors emphasize that aPLs are a heterogenous family of autoantibodies associated with a clinical syndrome characterized by thrombo-occlusive events. They include not only the aCLs (IgG and IgM) and the lupus anticoagulant but also the antibodies against β2-GPI and other specific proteins, such as antiphosphatidylinositol antibodies, antiphosphatidyl serine antibodies, and antiphosphatidylethanolamine antibodies.
30. 30 Levine SR, Salowitch-Palm L, Sawaya KL, Perry M, Spencer HJ, Winckler HJ, et al.: Anticardiolipin antibody titer > 40 GP L and the risk of subsequent thrombo-occlusive events and death: a prospective cohort study. Stroke 1997, 28:1660-1665.
31. 31 Finazzi G, Brancaccio V, Moia M, Ciavarella N, Mazzucconi G, Schinco PC, et al.: Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med 1996, 100:530-536.
32. 32 Tanne D, D'Olhaberriague L, Schultz LR, Salowich-Palm L, Sawaya KL, Levine SR: Anticardiolipin antibodies and their associations with cerebrovascular risk factors. Neurology 1999, 52:1368-1373. This prospective study of 749 patients, 300 of whom had stroke, found an association of stroke with multiple cerebrovascular risk factors, IgG isotype aCL greater than 20 GPL, and with higher immunoreactivity. These findings caution against overdiagnosis of the antiphospholipid syndrome and against excessive treatment of patients with multiple cerebrovascular risk factors. Ischemic stroke followed by the detection of aCL probably differs from aPS with subsequent stroke.
33. 33 Verro P, Levine SR, Tieften GE: Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke 1998, 29:2245-2253. In this prospective follow-up study of 27 consecutive patients with high positive IgG aCL titers (>100 GPL), the authors showed that recurrent cerebrovascular events were frequent (seen in 96% of patients) and that neurologic deficits were usually minor (in 63% of patients) with no disability-liter correlation.
34. 34 Rosse WF: Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 1997, 76:63-93.
35. 35 Hillmen P, Lewis SM, Bossier M, Luzzato L, Dacie JV: Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995, 333:1253-1258.
36. 36 Hauser D, Barzilai N, Zalish M, Oliver M, Pollack A: Bilateral papilledema with retinal hemorrhages in association with cerebral venous thrombosis and paroxysmal nocturnal hemoglobinuria. Am J Ophthalmol 1996, 122:592-593.
37. 37 Bick RL: Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemost 1998, 24:3-18. This paper discusses current concepts of the many complex pathophysiologic mechanisms and clinical and laboratory manifestations of disseminated intravascular coagulation.
38. 38 Francis JL, Biggerstaff J, Amirkhosravi A: Hemostasis and malignancy. Semin Thromb Hemost 1998, 24:93-109.
39. 39 Mammen EF: The haematological manifestations of sepsis. J Antimicrob Chemother 1998, 41 (suppl A): 17-24.
40. 40 Williamson TH, Rumley A, Lowe GDO: Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol 1996, 80:202-208.
41. 41 Arend O, Remky A, Jung F, Kiesewetter H, Reim M, Wolf S: Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 1996, 103:80-86.
42. 42 Giordano N, Senesi M, Battisti E, Traversi C, Mattii G, Palumba F, Gennari C: Antiphospholipid antibodies in patients with retinal vascular occlusions. Acta Ophthalmol Scand 1998, 76:128-129.
43. 43 Wiechens B, Schröder JO, Pötzsch B, Rochels R: Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am J Ophthalmol 1997, 123:848-850.
44. 44 Glacet-Bernard A, Bayani N, Chrétine P, Cochard C, Lelong F, Coscas G: Antiphospholipid antibodies in retinal vascular occlusions. Arch Ophthalmol 1994, 112:790-795.
45. 45 Linna T, Ylikorkala A, Kontula K, Puska P, Tervo T: Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997, 77:214-216.
46. 46 Greven CM, Wall AB: Peripheral retinal neovascularization and retinal vascular occlusion associated with activated protein C resistance. Am J Ophthalmol 1997, 124:687-689.
47. 47 The Eye Disease Case-Control Study Group: Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996, 114:545-554.
48. 48 Vine AK, Samama MM: Screening for resistance to activated protein C and the mutant gene for factor V: Q506 in patients with central retinal vein occlusion. Am J Ophthalmol 1997, 124:673-676.
49. 49 Spagnolo BV, Nasrallah FP: Bilateral retinal vein occlusion associated with factor V Leiden mutation. Retina 1998, 18:377-378.
50. 50 Enzenauer RW, Brozetti JT, Dragoo RA: Central retinal vein occlusion in a patient with IgG Lambda monoclonal gammopathy. Arch Ophthalmol 1999, 117:134-135.
51. 51 Iijima H, Gohdo T, Imai M, Tsukahara S: Thrombin-antithrombin III complex in acute retinal vein occlusion. Am J Ophthalmol 1998, 126:677-682.
52. 52 Hattenbach LO, Klais C, Scharrer I: Heparin cofactor II deficiency in central retinal vein occlusion. Acta Ophthalmol Scand 1998, 76:758-759.
53. 53 Lip PL, Blann AD, Jones AF, Lip GYH: Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye 1998, 12:245-251.
54. 54 Biousse V, Newman NJ, Sternberg P: Central retinal vein occlusion and transient monocular visual loss associated with hyperhomocysteinemia. Am J Ophthalmol 1997, 124:257-260.
55. 55 Biousse V, Bousser MG: Cerebral venous thrombosis. Neurologist, In press.
56. 56 Williamson TH: Central vein occlusion: what's the story? Br J Ophthalmol 1997, 81:698-704.
57. 57 Deschiens MA, Conard J, Horellou H, Ameri A, Preter M, Chedru F, et al.: Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996, 27:1724-1730.
58. 58 Zuber M, Toulon P, Marnet L, Mas JL: Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996, 27:1721-1723.
59. 59 Brey RL, Coull BM: Cerebral venous thrombosis. Role of activated protein C resistance and factor V gene mutation. Stroke 1996, 27:1719-1720.
60. 60 Martinelli I, Landi G, Maerati G, Cella R, Tosetto A, Mannucci PM: Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996, 75:393-394.
61. 61 Ludemann P, Nabavi DG, Junker R, Wolff E, Papke K, Buchner H, et al.: Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients. Stroke 1998, 29:2507-2510.
62. 62 Bloem BR, van Putten MJAM, van der Meer FJ, van Hilten JJ, Bertina RM: Superior sagittal sinus thrombosis in a patient heterozygous for the novel 20210A allele of the prothrombin gene. Thromb Haemost 1998, 79:235.
63. 63 Biousse V, Conard J, Brouzes C, Horellou MH, Ameri A, Bousser MG: Frequency of the 20210G→A mutation in the 3′-untranslated region of the prothrombin gene in 35 cases of cerebral venous thrombosis. Stroke 1998, 29: 1398-1400.
64. 64 Reuner KH, Ruf A, Grau A, Rickmann H, Stolz E, Juttler E, et al.: Prothrombin gene G20210→A transition is a risk factor for cerebral venous thrombosis. Stroke 1998, 29:1765-1769.
65. 65 Weih M, Mehraein S, Valdueza JM, Einhaüpl KM, Kulozik AE: Coincidence of factor V Leiden mutation and a mutation in the prothrombin gene at position 20210 in a patient with puerperal cerebral venous thrombosis. Stroke 1998, 29:1739-1740.
66. 66 Norlund L, Zöller B, Öhlin AK: A novel thrombomodulin gene mutation in a patient suffering from sagittal sinus thrombosis. Thromb Haemost 1997, 78: 1164-1166.
67. 67 DeVeber G, Monagle G, Chan A, MacGregor D, Curtis R, Lee S, et al.: Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol 1998, 55:1539-1543. In this prospective study, 92 children (newborn to 18 years of age) with arterial ischemic stroke (78%) or cerebral venous thrombosis (22%) were tested for prothrombotic disorders (workup included testing for plasminogen, proteins C and S, APC resistance, IgG and IgM aCLs, and lupus anticoagulant). Hypercoagulable states were found in 35 children (38%), and 21 of the 35 had more than one coagulation abnormality.
68. 68 Mas JL, Lamy CL: Stroke in pregnancy and in the puerperium. J Neurol 1998, 245:305-313.
69. 69 Longstreth WT Jr, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, et al.: Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G2010A). Stroke 1998, 29: 577-580. This case-control study studied the frequency of the factor V Leiden mutation and the G20210A prothrombin gene variant in 106 women with a first ischemic stroke (18 to 44 years of age) and 391 controls. Neither the factor V Leiden mutation nor the prothrombin variant was an important risk factor for stroke.
70. 70 The Antiphospholipid Antibodies in Stroke Study (APASS) Group: Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993, 43:2069-2073.
71. 71 Khamashata M, Guadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995, 332:993-997.
72. 72 The WARSS, APASS, PICSS, and HAS Study Groups: The feasibility of a collaborative double-blind study using an anticoagulant: the Warfarin-Aspirin Recurrent Stroke Study (WARSS), the Antiphospholipid Antibodies and Stroke Study (APASS), the Patient Foramen Ovale in Cryptogenic Stroke Study (PICSS), and the Hemostatic System Activation Study (HAS). Cerebrovasc Dis 1997, 7:100-112.
73. 73 Tayyanipour R, Pulido JS, Postel EA, Lipkowitz JL, Pisciotta A, Braza E: Arterial vascular occlusion associated with factor V Leiden gene mutation. Retina 1998, 18:376-377.
74. 74 Talmon T, Scharf J, Mayer E, Lanir N, Miller B, Brenner B: Retinal arterial occlusion in a child with factor V Leiden and thermolabile-methylene letrahydrofolate reductase mutations. Am J Ophthalmol 1997, 124:689-691.
75. 75 Levine SR, Crofts JW, Lesser GR, Floberg J, Welch KM: Visual symptoms associated with the presence of a lupus anticoagulant. Ophthalmology 1988, 95:686-692.
76. 76 Galetta SL, Plock GL, Kushner MJ, Wyszynski RE, Brucker AJ: Ocular thrombosis associated with antiphospholipid antibodies. Ann Ophthalmol 1991, 23:207-212.
77. 77 Lutty GA, Merges C, McLeod DS, Wajer SD, Suzuka SM, Fabry ME, Nagel RL: Nonperfusion of retina and choroid in transgenic mouse models of sickle cell disease. Curr Eye Res 1998, 17:438-444.
78. 78 Digre KB, Duncan FJ, Branch DW: Amaurosis fugax associated with antiphospholipid antibodies. Ann Neurol 1989, 25:228-232.
79. 79 Donders RCJM, Kappelle LJ, Derkson RHWM, Algra A, Horbach DA, de Grool PhG, van Gijn J: Transient monocular blindness and antiphospholipid antibodies in systemic lupus erythematosus. Neurology 1998, 51:535-540.
80. 80 Hayreth SS, Joos KM, Podhajsky PA, Long CR: Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994, 118:766-780.
81. 81 Jacobson DM, Vierkant RA, Belongia EA: Nonarteritic anterior ischemic optic neuropathy. A case-control study of potential risks factors. Arch Ophthalmol 1997, 115:1403-1407.
82. 82 Acheson JF, Sanders MD: Coagulation abnormalities in ischemic optic neuropathy. Eye 1994, 8:89-92.
83. 83 Worrall BB, Moazami G, Odel JG, Behrens MM: Anterior ischemic optic neuropathy and activated protein C resistance. A case report and review of the literature. J Neuroophthalmol 1997, 17:162-165.
84. 84 Salomon O, Huna-Baron R, Kurtz S, Steinberg D, Moisseiev J, Rosenberg N, et al.: Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1999, 196: 739-742. This was a small but well-designed case-control study of possible prothrombotic and vascular risk factors associated with anterior ischemic optic neuropathy. The authors noted no associations with potential thrombotic risk factors, such as protein C deficiency; protein S; antithrombin; lupus anticoagulant; aCLs; the factor V Leiden mutation; factor II G20210A polymorphism; MTHFR C677T polymorphism; or apolipoproteins E2, E3, and E4. They found that the vascular risk factots ischemic heart disease, hypercholesterolemia, and diabetes mellitus are significantly associated with NAION (odds ratios, 2.9, 2.6, and 2.3, respectively). They also noted an additive risk with ischemic heart disease and hypercholesterolemia (combined odds ratio, 4.5). No identified risk factors were associated with second eye involvement.
85. 85 Feldon SE: Anterior ischemic optic neuropathy: trouble waiting to happen. Ophthalmology 1999, 106:651-652. This excellent editorial summarizes our knowledge on the pathophysiology of NAION and the role of a coagulation workup.